Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zimmer (ZBH) Down 5.6% Since Last Earnings Report: Can It Rebound?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?

Style Box ETF report for IMCB

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.

Baxter International (BAX) Surpasses Q1 Earnings and Revenue Estimates

Baxter (BAX) delivered earnings and revenue surprises of 16.25% and 1.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

MedTech Stocks' Apr 28 Earnings Roster: ABMD, SYK & More

The MedTech companies' Q1 results are likely to reflect solid rebound in base business sales. Let's see how ABMD, SYK, BAX and DXCM are poised ahead of their earnings releases.

Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Baxter (BAX) Stock For Now

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Baxter (BAX) to Report Q1 Earnings: What's in the Offing?

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome

Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.

LHC Group (LHCG) Ties Up to Improve Home Health Services

LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.

Here's Why You Should Retain Baxter (BAX) Stock For Now

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Baxter (BAX) to Enhance Its Portfolio With Latest Partnership

Baxter's (BAX) latest strategic partnership with Digital Diagnostics is expected to expand its connected care diagnostics portfolio.

Medtronic's (MDT) Q3 Earnings Beat, Revenues Lag Estimates

Medtronic (MDT) registers organic growth in the Cardiovascular, Neuroscience and Diabetes segments in Q3.

NextGen (NXGN)-Verato Tie Up to Improve Patient Insights

NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.

Shockwave Medical (SWAV) Gains 3.2% Post Q4 Earnings Beat

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and expansion in gross margin.

Integer Holdings (ITGR) Q4 Earnings, Revenues Top Estimates

Integer Holdings' (ITGR) fourth-quarter results reflect robust segmental performances besides strength in the majority of the product lines.

Quidel (QDEL) Q4 Earnings Top Estimates, Margins Decline

Despite robust revenues from COVID-19 products, Quidel (QDEL) records an overall soft Q4 performance.

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

AMN Healthcare's (AMN) robust Q4 results demonstrate its segmental strength.

Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.

Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates

Baxter (BAX) delivered earnings and revenue surprises of 0.97% and 4.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BAX vs. SYK: Which Stock Should Value Investors Buy Now?

BAX vs. SYK: Which Stock Is the Better Value Option?

Baxter (BAX) to Report Q4 Earnings: What's in the Offing?

Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.

DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.